Back to GW Pharmaceuticals or All Sprays

Details provided are based upon best-known information made available to MedBud, please reconfirm with your pharmacy. This page was last updated:
MedBud typically only updates products when availability changes, or new information is provided. An availability status from several months ago can still be valid when a product remains in/out of stock, or has been discontinued.

Dosing Look-Up Table (Estimated)

0.01/g0.27/mg THC0.25/mg CBD
0.05/g1.35/mg THC1.25/mg CBD
0.1/g2.7/mg THC2.5/mg CBD
0.15/g4.05/mg THC3.75/mg CBD
0.2/g5.4/mg THC5/mg CBD
0.25/g6.75/mg THC6.25/mg CBD
0.3/g8.1/mg THC7.5/mg CBD
/gCalculate THCCalculate CBD

Please note values above are based on registered THC/CBD percentages, subject to ±10% allowed variance. Values provided are 'best case', losses to air during vaporisation or combustion will always occur.

Medication Details

Brand
Union Jack GW Pharmaceuticals
Designation
Sativex T27:C25
Chemotype
Type II: THC/CBD Mix
THC Potential Range (±10%)
2.43-2.97mg/ml
CBD Potential Range (±10%)
2.25-2.75mg/ml

Stock Availability

We provide stock/pharmacy information only for use by medical cannabis patients, clinicians and pharmacists*.

Best-Known Status: Available

We try to ascertain stock status strictly based on the importer/distributor supplying pharmacies. Availability at individual pharmacies will differ.

*Cannabis is a controlled-substance and can only be legally dispensed upon submission of a valid prescription from a prescribing clinic, ordinarily listed.

Main Partner Pharmacy

Pharmacy Distributor

  • No main partner pharmacy noted.
  • Eaststone

Dispensing Patient Pharmacies

  •  Logo

Sativex is a cannabis-based medicine that is sprayed into the mouth. It is used to treat the common multiple sclerosis (MS) symptom of muscle stiffness and spasms (known as ‘spasticity’). It is licensed in the UK for people with MS-related muscle spasticity that has not improved with other treatments.

Information provided could come from a third-party source, and may not accurately reflect characteristics of the medication we're associating it with - we primarily provide these descriptions for those interested in strain lineage and history, which could also be inaccurate. Any information which could be taken as medical advice should be strictly disregarded. Please consult your doctor regarding the suitability of medications for your condition(s).

Union Jack About Jazz Pharmaceuticals PLC

GW Pharmaceuticals Logo

British pharmaceutics company, a subsidiary of Jazz Pharmaceuticals.

GW Pharmaceuticals was founded in 1998 by doctors Geoffrey Guy and Brian Whittle. That year, they obtained a cultivation license from the United Kingdom Home Office and the MHRA, allowing the company to cultivate, possess and supply cannabis to conduct scientific research concerning medical cannabis.

Later in 1998, GW Pharmaceuticals entered into a contract with Hortapharm B.V., a cannabis research and development corporation based in Amsterdam.

In 2001, GW Pharmaceuticals listed on the Alternative Investment Market, the junior market of the London Stock Exchange. In May 2013, the company became dual-listed on the NASDAQ and AIM.

In 2014, the company made a deal with New York to develop clinical trials using cannabidiol (CBD) to treat children who suffer from seizures and other medical complications. In May 2021, Jazz Pharmaceuticals acquired the company.

jazzpharma.com

  Information provided is partially community sourced and may be outdated or otherwise incorrect. Please report any inaccuracies found by email.

NHS LogoFurther National Health-Service Information on Cannabis-Based Products for Medicinal Use (CBPMs)